We talk alot about consumer driven health care, and Health2.0 companies allowing patients to rate doctors. Something not dissimilar is starting to happen in China, but with no technology involved. Fascinating stuff.
Matthew Holt
CONSUMERS/QUALITY: LASIK–not as user friendly as it’s supposed to be
There’s been lots of BS about how the price reductions in those ads for LASIK "prove" that cash based consumer payment works in health care. I always thought they were like the teaser prices in travel adverts in the Sunday papers–only good if you were leaving Tuesday at midnight, staying 4 months, taking no luggage, and having to fly the plane yourself while the pilot takes a nap.
And now HSC shows that it’s not as advertised.
HSC president Paul Ginsburg, Ph.D., points out that current efforts to increase price transparency for health care services often downplay “the complexity of decisions about medical care, patients’ dependence on physicians for guidance about appropriate services, and the need for information on quality.”
Ginsburg cautions that simply giving consumers a price list of “a la carte” services does little to help them make informed choices about which providers will cost less for an episode of care, let alone which providers offer the best value — or the optimal combination of the lowest cost and highest quality.
The article also points out that insured people have different needs for price information than uninsured people. Insured people need to know what their costs will be under their insurance and benefit structure. And policymakers should be careful not to overlook the role of health plans in negotiating better prices and translating complex price and quality data into usable consumer information that can potentially help steer patients to lower-cost, higher-quality providers, the article notes. Researchers chose the LASIK market for in-depth analysis largely because the vision correction surgery is widely regarded as the self-pay market with the most favorable conditions for consumer shopping. LASIK is an elective, nonurgent, simple procedure, giving consumers time and ability to shop; screening exams are not required to obtain initial price quotes, keeping the dollar and time costs of shopping reasonable; and easy entry of providers (ophthalmologists) into the market has stimulated competition and kept prices down.
However, LASIK patients still face significant hurdles when shopping from inconsistent bundling of what’s included in the procedure price to misleading advertising to quality concerns.
— Inconsistent Bundling. The package of services included in LASIK procedure fees varies across providers. For example, one critical factor is whether the cost of enhancement surgery is included in the fee. A price quote that appears to be the best deal but does not include follow-up operations if needed might end up being the highest-price option.
— Misleading Advertising. Misleading offers for free consultations or for LASIK for $299 and promises that LASIK would eliminate the need for glasses and contacts for life have all come under scrutiny by state and federal regulators, resulting in enforcement actions and settlements to halt the misleading practices.
— Quality Issues. Many industry observers expressed concern that LASIK is regarded as a commodity by some consumers, leading them to shop only on price, when provider quality may vary considerably. Even when consumers are interested in obtaining quality information, the study finds that it is not easy; those wishing to compare provider quality must gather information on success and complication rates from each LASIK surgeon’s practice.
Which of course means that if we’re going to get to real consumer purchasing, we need to figure out a rational way to price for rational bundles of service–and we have to make sure that providers are showing apples to apples comparisons.
OFF-TOPIC: Your Friday warm fuzzies story
As a paraglider myself, I hope for luck this good for all paragliders.
German paraglider survives being sucked into killer storm
TECH/HEALTH PLANS: LA Times, day late and dollar short on Health Connect
Today’s LA Times has a long story about Kaiser’s Health Connect project. As far as I can tell it has no new information at all other than a quote from one pissed off employee who quit last week right at the end saying it was the worst project he’d ever seen, etc.
Otherwise it was a complete rehash of all the stuff that was in the blogs and in Computer World 3 months ago. And it missed the key issue—was KP’s Citrix-based strategy a fatal flaw, or is it just having teething problems. In other words, will HealthConnect work when it’s fully deployed, or is it doomed from the start? That’s what KP members and the rest of us should really be caring about.
Given the leading role the LA Times has played in breaking myriad issues concerning KP (the kidney transplant fiasco) and other California health plans (cancellations) in the last year, I’m confused as to how this shoddy summary—about something that the rest of us wrote about last year—got written so late in the day.
POLICY: Centrist democratic policy wonks talk shop
The Century Foundation has a discussion from a bunch of health care policy experts/pundits about the latest developments in the health reform “debate”. Given the large cast of characters (inc Aaron, Hacker, Relman and younger punks Cohn, Klein et al), it’s interesting stuff, but not exactly as diverse as say Cato’s recent back and forth! Yup, it’s a bunch of DimmyCrats talking to each other, but smart ones. Here’s the document. (rather annoyingly it’s a PDF).
PHARMA: The Future of Non-Profit Drug Development By Merrill Goozner
Merrill Goozner has been writing about economics and health care for many years. The former chief economics correspondent for the Chicago Tribune, Merrill has written for a long list of publications including the New York Times, The American Prospect and The Washington Post. His most recent book, "The $800 Million Dollar Pill – The Truth Behind the Cost of New Drugs " (University of California Press, 2004) has won acclaim from critics for its treatment of the issues facing the health care system and the pharmaceutical industry in particular. Today he has something to say about a familiar topic : the relationship between public sector R&D investment and innovation in the pharmaceutical and biotech industries. You can read more pieces by Merrill at Gooznews.com
The United States is the world leader in investing in biomedical
research and development. In the public sector, the National Institutes
of Health spent $28.6 billion in 2005, largely for basic science
research. The pharmaceutical industry spent an estimated $39 billion in
2004. This includes investment in the U.S. by U.S.-based firms,
investment overseas by U.S. firms, and foreign companies’ R&D
expenditures in the U.S. Indeed, over the past quarter century, the
private sector’s investment in the search for new medicines has grown
eight percent per year on average, faster than the industry’s growth in
sales and profits.
Despite this massive public and private effort, output, as measured
by the number of new drugs, biologics, vaccines and devices approved
for use by regulatory bodies like the U.S. Food and Drug
Administration, has slowed in recent years. Last year, the FDA approved
just 21 new drugs and biologics, the second lowest total since 1993.
Moreover, about half of these new drugs were not given priority status
by the FDA, which meant they were not considered a significant new
advance in medicine. This significance ratio has held steady for over a
decade. Clearly, the steady increase in private and public R&D
spending is generating diminishing returns, whether measured by return
on investment or public health.
PODCAST/TECH/QUALITY: MedEncentive–can a simply “elegant” solution really change health care delivery?
Jeff Greene believes that his "elegant" solution can change health care delivery in one of the toughest places in America to do it–the wild medical mid-west. Jeff claims that the only two places on earth where life expectancy is falling are sub-Saharan Africa and Oklahoma City. (I assume Iraq is soon joining that list!) His company MedEncentive offers a simple way of physicians to follow guidelines, patients to get informed about their care, and apparently payers to save lots of money. Before you dismiss it, listen to this podcast.
(Technical note–For some bizarre reason Jeff’s channel was recorded a few seconds ahead of mine. So he’s answering my questions a little before I’ve finished asking them. Or alternatively, he’s psychic. At any rate it sounds a little odd. But I know you lot never listen to me on these podcasts anyway!)
INTERNATIONAL: Gaming Choose & Book?
The Daily Mail, a British tabloid that is not exactly known for its rational, pro-Blairite analysis says that UK Hospitals are cheating over patient choice and gaming the Choose and Book system.
POLICY: Vic Fuchs still bringing it!
Vic Fuchs and Zeke Emmanuel body slam reform efforts that leave employment-based health care in the system.
TECH: HIMSS blogger meet-up
HIMSS blogger meet-up is on.
Sunday, February 25, 2007Time: 08:00 PM (right after the HIMSS Reception)Location: Mulate’s (Cajun restaurant and bar located right across from the convention center) — thanks to Tim Gee for this arrangement
Come meet Shahid Shah, Tim Gee, John Sharp, and guess whic one of the lurkers at the bar is really MrHISTalk….
This is so important that I’m flying in especially from London for it. Hope to see you there!